Multiple Myeloma Medications

Chemotherapy Medications Learn more >> More >>

DRUG	GENERIC NAME	DRUG INDICATION
Chemotherapy	Multiple	Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.
Farydak	panobinostat	Farydak is an HDAC inhibitor approved for multiple myeloma, in combination with dexamethasone and Velcade (bortezomib).
Xpovio	selinexor	Xpovio is the first approved nuclear export inhibitor. It is indicated for people with previously treated relapsed or refractory (nonresponsive) multiple myeloma or diffuse large B-cell lymphoma.

Immunotherapy Medications Learn more >> More >>

DRUG	GENERIC NAME	DRUG INDICATION
Pomalyst	pomalidomide	Pomalyst is an immunomodulator approved for multiple myeloma and Kaposi sarcoma.
Revlimid	lenalidomide	Revlimid is an immunomodulator approved for multiple myeloma in combination with dexamethasone, for follicular lymphoma and marginal zone lymphomain in combination with Rituxan (rituximab), and as a single drug for myelodysplastic syndromes and mantle cell lymphoma.
Thalomid	thalidomide	Thalomid is an immunomodulator approved for multiple myeloma, in combination with dexamethasone.

Targeted Therapy Medications Learn more >> More >>

DRUG	GENERIC NAME	DRUG INDICATION
Blenrep	belantamab mafodotin	Blenrep is a BCMA-directed antibody-drug conjugate approved for people with heavily pretreated relapsed or refractory multiple myeloma.
Darzalex, Darzalex Faspro	daratumumab	Darzalex is a CD38 inhibitor approved for newly diagnosed or previously multiple myeloma, in combination with various other medications. Darzalex Faspro is a newer formulation that can be given by subcutaneous injection rather than IV infusion.
Empliciti	elotuzumab	Empliciti is a SLAMF7 inhibtor approved multiple myeloma, in combination with dexamethasone and Revlimid (lenalidomide).
Kyprolis	carfilzomib	Kyprolis is a proteasome inhibitor approved for relapsed or refractory multiple myeloma, used alone or in combination with other medications.
Ninlaro	ixazomib	Ninlaro is a proteasome inhibitor approved multiple myeloma, in combination with dexamethasone and Revlimid (lenalidomide).
Sarclisa	isatuximab-irfc	Sarclisa is a CD38 inhibitor approved for combination treatment of multiple myeloma in previously treated people.
Velcade	bortezomib	Velcade is a proteasome inhibitor approved for multiple myeloma and mantle cell lymphoma.

Chemotherapy Medications More >>

DRUG Chemotherapy
GENERIC NAME Multiple
DRUG INDICATION Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

DRUG Farydak
GENERIC NAME panobinostat
DRUG INDICATION Farydak is an HDAC inhibitor approved for multiple myeloma, in combination with dexamethasone and Velcade (bortezomib).

DRUG Xpovio
GENERIC NAME selinexor
DRUG INDICATION Xpovio is the first approved nuclear export inhibitor. It is indicated for people with previously treated relapsed or refractory (nonresponsive) multiple myeloma or diffuse large B-cell lymphoma.

Immunotherapy Medications More >>

DRUG Pomalyst
GENERIC NAME pomalidomide
DRUG INDICATION Pomalyst is an immunomodulator approved for multiple myeloma and Kaposi sarcoma.

DRUG Revlimid
GENERIC NAME lenalidomide
DRUG INDICATION Revlimid is an immunomodulator approved for multiple myeloma in combination with dexamethasone, for follicular lymphoma and marginal zone lymphomain in combination with Rituxan (rituximab), and as a single drug for myelodysplastic syndromes and mantle cell lymphoma.

DRUG Thalomid
GENERIC NAME thalidomide
DRUG INDICATION Thalomid is an immunomodulator approved for multiple myeloma, in combination with dexamethasone.

Targeted Therapy Medications More >>

DRUG Blenrep
GENERIC NAME belantamab mafodotin
DRUG INDICATION Blenrep is a BCMA-directed antibody-drug conjugate approved for people with heavily pretreated relapsed or refractory multiple myeloma.

DRUG Darzalex, Darzalex Faspro
GENERIC NAME daratumumab
DRUG INDICATION Darzalex is a CD38 inhibitor approved for newly diagnosed or previously multiple myeloma, in combination with various other medications. Darzalex Faspro is a newer formulation that can be given by subcutaneous injection rather than IV infusion.

DRUG Empliciti
GENERIC NAME elotuzumab
DRUG INDICATION Empliciti is a SLAMF7 inhibtor approved multiple myeloma, in combination with dexamethasone and Revlimid (lenalidomide).

DRUG Kyprolis
GENERIC NAME carfilzomib
DRUG INDICATION Kyprolis is a proteasome inhibitor approved for relapsed or refractory multiple myeloma, used alone or in combination with other medications.

DRUG Ninlaro
GENERIC NAME ixazomib
DRUG INDICATION Ninlaro is a proteasome inhibitor approved multiple myeloma, in combination with dexamethasone and Revlimid (lenalidomide).

DRUG Sarclisa
GENERIC NAME isatuximab-irfc
DRUG INDICATION Sarclisa is a CD38 inhibitor approved for combination treatment of multiple myeloma in previously treated people.

DRUG Velcade
GENERIC NAME bortezomib
DRUG INDICATION Velcade is a proteasome inhibitor approved for multiple myeloma and mantle cell lymphoma.